Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:34 AM
Ignite Modification Date:
2025-12-26 @ 10:34 AM
NCT ID:
NCT06022328
Eligibility Criteria:
Inclusion Criteria:
For the 110 patients with MPN:
* Patients with PV, ET or PMF
* DNA extracted from purified granulocytes at time of diagnosis
* No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)
For the 10 subjects without MPN:
* Absence of hematological malignancy
* Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia
* Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular)
Exclusion Criteria:
For the 110 patients with MPN:
* Patients without PV, ET or PMF
* Patients without purified granulocytes DNA available at time of diagnosis
* Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
* Patients with less than 2 years' follow-up
For the 10 subjects in NMP :
* Patients with hematological malignancy and/or solid cancer
* Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06022328
Study Brief:
Protocol Section:
NCT06022328